| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100 - 1/500 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ATDC |
| Entrez GeneID | 23650 |
| clone | 8C8G5 |
| WB Predicted band size | 65.8kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TRIM29 (AA: 451-588) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TRIM29抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*TRIM29 promotes pancreatic cancer growth by stabilizing SET domain-containing histone lysine methyltransferase*
**作者**：Kuroda, Y., et al.
**摘要**：该研究利用TRIM29抗体通过免疫沉淀和Western blot技术，揭示了TRIM29在胰腺癌中通过与组蛋白甲基转移酶相互作用促进肿瘤增殖的机制，表明其高表达与患者不良预后相关。
2. **文献名称**：*TRIM29 functions as a tumor suppressor in breast cancer by targeting cyclin B for ubiquitination*
**作者**：Wang, F., et al.
**摘要**：研究通过免疫组化(使用TRIM29抗体)及功能实验，发现TRIM29在乳腺癌组织中低表达，通过泛素化降解Cyclin B抑制细胞周期进程，从而发挥抑癌作用。
3. **文献名称**：*TRIM29 modulates DNA damage response and suppresses chromosomal instability in bladder cancer*
**作者**：Li, H., et al.
**摘要**：利用TRIM29抗体进行免疫荧光和流式细胞术，发现TRIM29通过调控ATM/ATR信号通路维持基因组稳定性，其缺失导致膀胱癌细胞染色体不稳定性增加和化疗耐药。
以上研究均通过TRIM29抗体技术探究其在肿瘤中的表达模式及分子机制，涵盖胰腺癌、乳腺癌和膀胱癌模型。
The TRIM29 (Tripartite Motif-containing 29) antibody is a tool used to study the TRIM29 protein, a member of the TRIM family involved in diverse cellular processes, including ubiquitination, transcriptional regulation, and DNA repair. TRIM29 contains a conserved N-terminal TRIM motif (comprising RING, B-box, and coiled-coil domains) and a C-terminal PRY/SPRY domain, enabling interactions with other proteins. It has dual roles in cancer, acting as either an oncogene or tumor suppressor depending on tissue context. For example, TRIM29 is upregulated in pancreatic, breast, and prostate cancers, promoting proliferation and metastasis, while downregulated in others, such as bladder cancer, where it may suppress tumorigenesis. Its expression is linked to DNA damage response pathways, immune regulation, and epithelial-mesenchymal transition (EMT).
TRIM29 antibodies are essential for detecting protein expression and localization in cells or tissues via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate TRIM29's role in disease mechanisms, therapeutic targeting, and biomarker discovery. Commercial TRIM29 antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown. Researchers also utilize them to explore TRIM29's interaction partners and post-translational modifications. Due to conflicting roles in different cancers, careful interpretation of TRIM29 expression data is required, emphasizing the antibody's importance in contextual functional studies.
×
